Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease

增强小胶质细胞的植入以治疗神经系统疾病

• 批准号: 10382086
• 负责人: Sunil Gandhi
• 金额: $ 39.99万
• 依托单位: NOVOGLIA, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10382086
• 关键词: Adult; Alzheimer' s Disease; Animals; Basic Science; Biological Assay; Brain; CSF1R gene; Cell Line; Cell Survival; Cells; Chimerism; Complex; Corpus striatum structure; Couples; Data; Development; Dimethyl Sulfoxide; Disease; Dose; Drug resistance; Engineering; Engraftment; Excision; Flow Cytometry; Frontotemporal Dementia; Genes; Genomics; Hippocampus (Brain); Homeostasis; Human; Immune; Immunohistochemistry; In Vitro; Injections; Legal patent; Licensing; Lipopolysaccharides; Lysosomal Storage Diseases; Measures; Microglia; Mouse Cell Line; Mucopolysaccharidosis III; Mus; Mutation; Neoplasms; Neurodegenerative Disorders; Oral; Pathology; Patients; Pharmaceutical Preparations; Phase; Phosphorylation; Play; Population; Production; Prosencephalon; Receptor Signaling; Research; Resistance; Role; Saline; Supportive care; Technology; Therapeutic; Tissues; Transplantation; Tyrosine; Ursidae Family; Work; base; brain cell; brain tissue; cellular engineering; density; drug discovery; effective therapy; experimental study; frontal lobe; genetically modified cells; human pluripotent stem cell; in vivo; induced pluripotent stem cell; inhibitor; loss of function; nervous system disorder; novel; novel strategies; novel therapeutics; pathogen; postnatal; preclinical safety; precursor cell; preservation; response to injury; small molecule inhibitor; standard of care; success; transcriptome; transcriptomics; treatment strategy

There are no effective treatments for microgliopathies, a class of neurodegenerative disorders that are caused by the absence or misfunction of specialized cells in the brain, called microglia. One potential strategy to treat patients with a microgliopathy is to replace their diseased microglia with new cells. The NovoGlia technology platform uses induced pluripotent stem cells to generate new microglia cells at high scale and with high purity. NovoGlia cells can be safely and effectively transplanted into the brains of young mice, in which endogenous microglia are still developing, yet strategies that enable high levels of microglial chimerism within adult brains with a fully occupied niche have yet to be developed. The objective of this proposal is to demonstrate the feasibility of a novel approach that combines the depletion of endogenous microglia using a commercially available drug with the transplantation of NovoGlia cells that are engineered to be resistant to the small molecule inhibitor. NovoGlia developed two novel cell lines that bear mutations making them resistant to the drug, and demonstrated their viability in cell-based experiments, confirmed their microglia transcriptomic profile, and demonstrated drug resistance in cell-based assay. Aim 1 will confirm the in vivo transcriptomic and functional preservation of the novel cell lines. Aim 2 will measure the success NovoGlia cell replacement in the presence of variable doses of inhibitor in vivo, and Aim 3 will optimize the NovoGlia cell replacement strategy. Successful completion of these Aims is a necessary first step in developing new commercial therapeutics for the treatment of microgliopathies and potentially other neurodegenerative diseases. Phase I results will provide proof-of- concept data to support the continued development of NovoGlia therapies for microgliopathies and other neurodegenerative diseases.

小神经胶质病是一种神经退行性疾病，目前尚无有效的治疗方法